CV.

Martin Rasmussen is the Global lead on serialisation activities in Lundbeck; His overall responsibility is to secure that Lundbeck is in compliance with legislation globally on serialisation and track & trace. He establishes plans and cross organisational alignment on activities to be in compliance with future legislation when implemented. Along that, Martin Senior Project Manager Product Introduction; Establish supply chain for new products, new markets, and life cycle management of existing products. Martin is a subject matter expert for  injection devices, he engages in support activities in SOE, R&D and Marketing on injection devices.His current focus lies on project proposals for EU’s Framework Programme for Research and innovation.

 

• 2014  H. Lundbeck A/S, Global Supply Chain, Senior Project Manager, Product Introduction
• 2013-2014 Novo Nordisk A/S Device R&D, Senior R&D Systems engineer and team coordinator.
• 2009-2013 Novo Nordisk A/S Device R&D, Lead engineer, mechanical design and team coordinator.
• 2006-2009 IPU Product Development, Engineering Consultant. 2005-2006 PERA Innovation UK, Project consultant and R&D engineer.

 

Education 1999-2005 Master of Science in Engineering, Technical University of Denmark. Degree in mechanical design and applied mechanics.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.